Howard Capital Management Group LLC Raises Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Howard Capital Management Group LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,894 shares of the medical research company’s stock after acquiring an additional 1,860 shares during the quarter. IQVIA comprises approximately 1.6% of Howard Capital Management Group LLC’s holdings, making the stock its 26th biggest holding. Howard Capital Management Group LLC owned approximately 0.07% of IQVIA worth $23,953,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. lifted its stake in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB lifted its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Versor Investments LP purchased a new position in IQVIA in the 3rd quarter worth approximately $1,328,000. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc raised its stake in shares of IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. Barclays dropped their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, BTIG Research cut their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

Check Out Our Latest Research Report on IQV

IQVIA Stock Performance

Shares of NYSE IQV opened at $205.23 on Wednesday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $37.25 billion, a PE ratio of 26.93, a P/E/G ratio of 2.01 and a beta of 1.48. The stock has a 50 day simple moving average of $199.69 and a 200-day simple moving average of $221.32.

About IQVIA

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.